BiotechTube

[Ga-68]-PNT6555 + [Lu-177]-PNT6555

Phase 1Terminated
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pancreatic Ductal Adenocarcinoma

Conditions

Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Esophageal Cancer, Melanoma (Skin), Soft Tissue Sarcoma, Head and Neck Squamous Cell Carcinoma, Cholangiocarcinoma

Trial Timeline

Jul 13, 2022 → Oct 2, 2024

NCT ID
NCT05432193

About [Ga-68]-PNT6555 + [Lu-177]-PNT6555

[Ga-68]-PNT6555 + [Lu-177]-PNT6555 is a phase 1 stage product being developed by Eli Lilly for Pancreatic Ductal Adenocarcinoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT05432193. Target conditions include Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Esophageal Cancer.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT05432193Phase 1Terminated

Competing Products

20 competing products in Pancreatic Ductal Adenocarcinoma

See all competitors
ProductCompanyStageHype Score
Autologous Mesothelin-specific TCR-T Cells + Cyclophosphamide + Fludarabine + BendamustineLonzaPhase 1
30
pemetrexedEli LillyPhase 2
52
mFOLFIRINOX + RamucirumabEli LillyPhase 2
52
[203Pb]Pb-PSV359 + [212Pb]Pb-PSV359Perspective TherapeuticsPhase 1/2
33
Zentalis + GemzarZentalis PharmaceuticalsPhase 2
44
enzastaurin + gemcitabineEli LillyPhase 2
52
Cyclophosphamide + GVAX Pancreas Vaccine (GVAX) + Pembrolizumab + IMC-CS4Eli LillyPhase 1
33
RamucirumabEli LillyPhase 1/2
41
GEMZAR + ALIMTAEli LillyPhase 3
77
CS-1008 (humanized anti-DR5 antibody) + gemcitabineDaiichi SankyoPhase 2
52
exatecan mesylateDaiichi SankyoPhase 2
52
exatecan mesylate + gemcitabine hydrochlorideDaiichi SankyoPhase 3
77
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
AGS-1C4D4 + gemcitabineAstellas PharmaPhase 2
52
erlotinib + gemcitabine + nab-paclitaxelAstellas PharmaPhase 1
33
erlotinib hydrochloride + gemcitabine hydrochlorideAstellas PharmaPhase 1
33
AGS-1C4D4 + GemcitabineAstellas PharmaPhase 2
52
Tarceva (erlotinib HCl, OSI-774)Astellas PharmaPhase 3
77
Enzalutamide + Gemcitabine + Nab-paclitaxelAstellas PharmaPhase 1
33

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved
85
Olanzapine + PlaceboApproved
85
exenatide and sitagliptin + exenatide and placeboApproved
85
Tirzepatide + PlaceboApproved
85
tadalafilApproved
85